Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.

Trial Details

NCT ID
NCT04459065
Phase
PHASE1 / PHASE2
Sponsor
University of Saskatchewan
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IRDye800CW-nimotuzumab
Locations (sample)
  • Saskatoon, Saskatchewan, Canada|52.13238,-106.66892

Key Eligibility Criteria

  • Surgically resectable Stage I and II non-small cell lung cancer
  • Able to give informed consent
  • Age ≥ 18 and ≤ 80 years old
  • Adequate cardiopulmonary reserve to undergo lung resection as determined by operating surgeon

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →